OSI-420 – Targeting the ubiquitin–proteasome system for cancer therapy

AMP-activated protein kinase (AMPK), a significant downstream effector from the tumor

March 10, 2019 by Katherine Lewis Leave a Comment

AMP-activated protein kinase (AMPK), a significant downstream effector from the tumor suppressor liver organ kinase 1 (LKB1) and pharmacologic target of metformin, established fact to exert a precautionary and inhibitory influence on tumorigenesis; nevertheless, its part in tumor development and metastasis is not well characterized. presented by multiple hamartomatous polyps in the gastrointestinal system (Alessi … [Read more…]

The scientific outcome of adoptive T cell transfer-based immunotherapies is often

August 3, 2017 by Katherine Lewis Leave a Comment

The scientific outcome of adoptive T cell transfer-based immunotherapies is often limited due to different escape mechanisms established by tumors in order to evade the hosts’ immune system. Based on the profiling data of these T cell subpopulations under the numerous conditions a series of differentially indicated spots were defined members thereof recognized by mass … [Read more…]